Clinical Efficacy and Safety of a Modified Conditioning Regimen Reducing the Dosage of Busulfan and Adding Thiotepa in Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Myeloid Leukemia.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
OBJECTIVE: This study aimed to investigate the efficacy and safety of allogeneic hematopoietic stem cell transplantation (allo-HSCT) with a conditioning regimen that reduces the dosage of busulfan and incorporates thiotepa in children with acute myeloid leukemia (AML). METHODS: A retrospective analysis was conducted on 55 pediatric patients with AML who underwent allo-HSCT at Hunan Children's Hospital from December 2019 to December 2023. Group A (n = 33) included patients with thiotepa in the conditioning regimen, while Group B (n = 22) included patients without thiotepa. Conditioning regemen of Group A was modified to reduce 1 day dosage of busulfan and add an additional dose of thiotepa at 10 mg/kg. RESULTS: With a median follow-up of 31 months, the OS for all patients was 94.5%. Group A had a higher survival rate compared to Group B, though the difference was not statistically significant (96.9% vs 90.9%, P = .388). For patients who were measurable residual disease positive before transplantation, the OS in Group A was significantly higher than in Group B (100% vs 75%, P = .039). The total relapse rate was 5.45%, with no significant difference between the groups (Group A 6% vs Group B 4.55%, P = .648). The non-relapse mortality was 1.8%, with only 1 death due to severe sinusoidal obstruction syndrome (SOS) in Group B. The incidence rates of acute graft-versus-host disease (aGVHD), severe aGVHD, SOS, and transplant-associated thrombotic microangiopathy (TA-TMA) were lower in Group A, particularly for aGVHD and severe aGVHD (30.3% vs 45.4%, P = .252; 12.1% vs 27.3%, P = .175), although these differences were not statistically significant. CONCLUSION: The modified conditioning regimen demonstrated promising clinical efficacy and safety. This modified regimen has the potential to enhance the prognosis of pediatric AML patients, especially those with MRD-positive pre-transplantation.